MEDPACE HOLDINGS INC (MEDP) Fundamental Analysis & Valuation

NASDAQ:MEDP • US58506Q1094

477.72 USD
+10.93 (+2.34%)
At close: Mar 11, 2026
477.7 USD
-0.02 (0%)
After Hours: 3/11/2026, 8:10:37 PM

This MEDP fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

Fundamental Rating

7

MEDP gets a fundamental rating of 7 out of 10. The analysis compared the fundamentals against 57 industry peers in the Life Sciences Tools & Services industry. Both the health and profitability get an excellent rating, making MEDP a very profitable company, without any liquidiy or solvency issues. MEDP is growing strongly while it is still valued neutral. This is a good combination! This makes MEDP very considerable for growth and quality investing!


Dividend Valuation Growth Profitability Health

9

1. MEDP Profitability Analysis

1.1 Basic Checks

  • MEDP had positive earnings in the past year.
  • MEDP had a positive operating cash flow in the past year.
  • MEDP had positive earnings in each of the past 5 years.
  • Each year in the past 5 years MEDP had a positive operating cash flow.
MEDP Yearly Net Income VS EBIT VS OCF VS FCFMEDP Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 200M 400M 600M

1.2 Ratios

  • The Return On Assets of MEDP (22.84%) is better than 98.25% of its industry peers.
  • The Return On Equity of MEDP (98.27%) is better than 100.00% of its industry peers.
  • Looking at the Return On Invested Capital, with a value of 71.19%, MEDP belongs to the top of the industry, outperforming 100.00% of the companies in the same industry.
  • MEDP had an Average Return On Invested Capital over the past 3 years of 49.20%. This is significantly above the industry average of 11.85%.
  • The 3 year average ROIC (49.20%) for MEDP is below the current ROIC(71.19%), indicating increased profibility in the last year.
Industry RankSector Rank
ROA 22.84%
ROE 98.27%
ROIC 71.19%
ROA(3y)19.71%
ROA(5y)17.64%
ROE(3y)65.94%
ROE(5y)56.06%
ROIC(3y)49.2%
ROIC(5y)40.37%
MEDP Yearly ROA, ROE, ROICMEDP Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20 40 60 80

1.3 Margins

  • MEDP's Profit Margin of 17.83% is amongst the best of the industry. MEDP outperforms 85.96% of its industry peers.
  • In the last couple of years the Profit Margin of MEDP has grown nicely.
  • The Operating Margin of MEDP (21.14%) is better than 89.47% of its industry peers.
  • MEDP's Operating Margin has improved in the last couple of years.
  • With a Gross Margin value of 30.06%, MEDP is not doing good in the industry: 73.68% of the companies in the same industry are doing better.
  • In the last couple of years the Gross Margin of MEDP has remained more or less at the same level.
Industry RankSector Rank
OM 21.14%
PM (TTM) 17.83%
GM 30.06%
OM growth 3Y3.46%
OM growth 5Y3.23%
PM growth 3Y2.01%
PM growth 5Y2.64%
GM growth 3Y0.5%
GM growth 5Y-0.03%
MEDP Yearly Profit, Operating, Gross MarginsMEDP Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 10 20 30 40

8

2. MEDP Health Analysis

2.1 Basic Checks

  • With a Return on Invested Capital (ROIC) well above the Cost of Capital (WACC), MEDP is creating value.
  • The number of shares outstanding for MEDP has been reduced compared to 1 year ago.
  • The number of shares outstanding for MEDP has been reduced compared to 5 years ago.
  • There is no outstanding debt for MEDP. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
MEDP Yearly Shares OutstandingMEDP Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 10M 20M 30M 40M
MEDP Yearly Total Debt VS Total AssetsMEDP Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 500M 1B 1.5B 2B

2.2 Solvency

  • MEDP has an Altman-Z score of 7.00. This indicates that MEDP is financially healthy and has little risk of bankruptcy at the moment.
  • MEDP has a better Altman-Z score (7.00) than 91.23% of its industry peers.
  • There is no outstanding debt for MEDP. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Altman-Z 7
ROIC/WACC6.53
WACC10.91%
MEDP Yearly LT Debt VS Equity VS FCFMEDP Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 200M 400M 600M 800M

2.3 Liquidity

  • MEDP has a Current Ratio of 0.74. This is a bad value and indicates that MEDP is not financially healthy enough and could expect problems in meeting its short term obligations.
  • The Current ratio of MEDP (0.74) is worse than 94.74% of its industry peers.
  • A Quick Ratio of 0.74 indicates that MEDP may have some problems paying its short term obligations.
  • With a Quick ratio value of 0.74, MEDP is not doing good in the industry: 92.98% of the companies in the same industry are doing better.
  • MEDP does not score too well on the current and quick ratio evaluation. However, as it has excellent solvency and profitability, these ratios do not necessarly indicate liquidity issues and need to be evaluated against the specifics of the business.
Industry RankSector Rank
Current Ratio 0.74
Quick Ratio 0.74
MEDP Yearly Current Assets VS Current LiabilitesMEDP Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 200M 400M 600M 800M 1B

8

3. MEDP Growth Analysis

3.1 Past

  • The Earnings Per Share has grown by an impressive 21.14% over the past year.
  • Measured over the past years, MEDP shows a very strong growth in Earnings Per Share. The EPS has been growing by 31.30% on average per year.
  • MEDP shows quite a strong growth in Revenue. In the last year, the Revenue has grown by 19.97%.
  • The Revenue has been growing by 22.27% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)21.14%
EPS 3Y27.86%
EPS 5Y31.3%
EPS Q2Q%27.25%
Revenue 1Y (TTM)19.97%
Revenue growth 3Y20.12%
Revenue growth 5Y22.27%
Sales Q2Q%32.03%

3.2 Future

  • Based on estimates for the next years, MEDP will show a quite strong growth in Earnings Per Share. The EPS will grow by 10.52% on average per year.
  • MEDP is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 9.03% yearly.
EPS Next Y13.94%
EPS Next 2Y12.47%
EPS Next 3Y12.37%
EPS Next 5Y10.52%
Revenue Next Year11.75%
Revenue Next 2Y9.61%
Revenue Next 3Y9.54%
Revenue Next 5Y9.03%

3.3 Evolution

  • Although the future EPS growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
MEDP Yearly Revenue VS EstimatesMEDP Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 1B 2B 3B 4B
MEDP Yearly EPS VS EstimatesMEDP Yearly EPS VS EstimatesYearly EPS VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 10 20 30

4

4. MEDP Valuation Analysis

4.1 Price/Earnings Ratio

  • Based on the Price/Earnings ratio of 31.22, the valuation of MEDP can be described as expensive.
  • Based on the Price/Earnings ratio, MEDP is valued a bit cheaper than 61.40% of the companies in the same industry.
  • MEDP is valuated at similar levels of the S&P average when we compare the Price/Earnings ratio to 26.15, which is the current average of the S&P500 Index.
  • Based on the Price/Forward Earnings ratio of 27.40, the valuation of MEDP can be described as expensive.
  • Compared to the rest of the industry, the Price/Forward Earnings ratio of MEDP indicates a somewhat cheap valuation: MEDP is cheaper than 63.16% of the companies listed in the same industry.
  • When comparing the Price/Forward Earnings ratio of MEDP to the average of the S&P500 Index (24.27), we can say MEDP is valued inline with the index average.
Industry RankSector Rank
PE 31.22
Fwd PE 27.4
MEDP Price Earnings VS Forward Price EarningsMEDP Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30

4.2 Price Multiples

  • Based on the Enterprise Value to EBITDA ratio, MEDP is valued a bit cheaper than 61.40% of the companies in the same industry.
  • Compared to the rest of the industry, the Price/Free Cash Flow ratio of MEDP indicates a somewhat cheap valuation: MEDP is cheaper than 78.95% of the companies listed in the same industry.
Industry RankSector Rank
P/FCF 19.88
EV/EBITDA 23.2
MEDP Per share dataMEDP EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 20 40 60 80

4.3 Compensation for Growth

  • The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates MEDP does not grow enough to justify the current Price/Earnings ratio.
  • MEDP has an outstanding profitability rating, which may justify a higher PE ratio.
  • MEDP's earnings are expected to grow with 12.37% in the coming years. This may justify a more expensive valuation.
PEG (NY)2.24
PEG (5Y)1
EPS Next 2Y12.47%
EPS Next 3Y12.37%

0

5. MEDP Dividend Analysis

5.1 Amount

  • No dividends for MEDP!.
Industry RankSector Rank
Dividend Yield 0%

MEDP Fundamentals: All Metrics, Ratios and Statistics

MEDPACE HOLDINGS INC

NASDAQ:MEDP (3/11/2026, 8:10:37 PM)

After market: 477.7 -0.02 (0%)

477.72

+10.93 (+2.34%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)02-09
Earnings (Next)04-20
Inst Owners84.9%
Inst Owner Change-2.17%
Ins Owners0.51%
Ins Owner Change-4.97%
Market Cap13.56B
Revenue(TTM)2.53B
Net Income(TTM)451.12M
Analysts70.53
Price Target497.46 (4.13%)
Short Float %5.69%
Short Ratio3.99
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)8.54%
Min EPS beat(2)7.52%
Max EPS beat(2)9.56%
EPS beat(4)4
Avg EPS beat(4)9.37%
Min EPS beat(4)2.57%
Max EPS beat(4)17.84%
EPS beat(8)8
Avg EPS beat(8)12.36%
EPS beat(12)11
Avg EPS beat(12)11.35%
EPS beat(16)15
Avg EPS beat(16)14.34%
Revenue beat(2)2
Avg Revenue beat(2)0.84%
Min Revenue beat(2)0.75%
Max Revenue beat(2)0.93%
Revenue beat(4)4
Avg Revenue beat(4)3.88%
Min Revenue beat(4)0.75%
Max Revenue beat(4)9.78%
Revenue beat(8)4
Avg Revenue beat(8)0.78%
Revenue beat(12)7
Avg Revenue beat(12)1.31%
Revenue beat(16)10
Avg Revenue beat(16)1.28%
PT rev (1m)-10.76%
PT rev (3m)-9.07%
EPS NQ rev (1m)1.41%
EPS NQ rev (3m)2.01%
EPS NY rev (1m)3.71%
EPS NY rev (3m)3.81%
Revenue NQ rev (1m)2.43%
Revenue NQ rev (3m)2.44%
Revenue NY rev (1m)-0.21%
Revenue NY rev (3m)-0.17%
Valuation
Industry RankSector Rank
PE 31.22
Fwd PE 27.4
P/S 5.36
P/FCF 19.88
P/OCF 19.01
P/B 29.53
P/tB N/A
EV/EBITDA 23.2
EPS(TTM)15.3
EY3.2%
EPS(NY)17.43
Fwd EY3.65%
FCF(TTM)24.03
FCFY5.03%
OCF(TTM)25.13
OCFY5.26%
SpS89.16
BVpS16.18
TBVpS-8.34
PEG (NY)2.24
PEG (5Y)1
Graham Number74.62
Profitability
Industry RankSector Rank
ROA 22.84%
ROE 98.27%
ROCE 84.68%
ROIC 71.19%
ROICexc 333.94%
ROICexgc N/A
OM 21.14%
PM (TTM) 17.83%
GM 30.06%
FCFM 26.95%
ROA(3y)19.71%
ROA(5y)17.64%
ROE(3y)65.94%
ROE(5y)56.06%
ROIC(3y)49.2%
ROIC(5y)40.37%
ROICexc(3y)169.04%
ROICexc(5y)114.84%
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)58.52%
ROCE(5y)48.87%
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3Y101.11%
ROICexc growth 5Y74.12%
OM growth 3Y3.46%
OM growth 5Y3.23%
PM growth 3Y2.01%
PM growth 5Y2.64%
GM growth 3Y0.5%
GM growth 5Y-0.03%
F-Score7
Asset Turnover1.28
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Debt/EBITDA 0
Cap/Depr 111.49%
Cap/Sales 1.24%
Interest Coverage 250
Cash Conversion 126.67%
Profit Quality 151.15%
Current Ratio 0.74
Quick Ratio 0.74
Altman-Z 7
F-Score7
WACC10.91%
ROIC/WACC6.53
Cap/Depr(3y)125.21%
Cap/Depr(5y)134.9%
Cap/Sales(3y)1.64%
Cap/Sales(5y)1.98%
Profit Quality(3y)144.35%
Profit Quality(5y)141.17%
High Growth Momentum
Growth
EPS 1Y (TTM)21.14%
EPS 3Y27.86%
EPS 5Y31.3%
EPS Q2Q%27.25%
EPS Next Y13.94%
EPS Next 2Y12.47%
EPS Next 3Y12.37%
EPS Next 5Y10.52%
Revenue 1Y (TTM)19.97%
Revenue growth 3Y20.12%
Revenue growth 5Y22.27%
Sales Q2Q%32.03%
Revenue Next Year11.75%
Revenue Next 2Y9.61%
Revenue Next 3Y9.54%
Revenue Next 5Y9.03%
EBIT growth 1Y19.71%
EBIT growth 3Y24.28%
EBIT growth 5Y26.22%
EBIT Next Year16.28%
EBIT Next 3Y12.32%
EBIT Next 5Y10.93%
FCF growth 1Y19.15%
FCF growth 3Y24.75%
FCF growth 5Y24.56%
OCF growth 1Y17.15%
OCF growth 3Y22.49%
OCF growth 5Y22.49%

MEDPACE HOLDINGS INC / MEDP FAQ

What is the fundamental rating for MEDP stock?

ChartMill assigns a fundamental rating of 7 / 10 to MEDP.


Can you provide the valuation status for MEDPACE HOLDINGS INC?

ChartMill assigns a valuation rating of 5 / 10 to MEDPACE HOLDINGS INC (MEDP). This can be considered as Fairly Valued.


What is the profitability of MEDP stock?

MEDPACE HOLDINGS INC (MEDP) has a profitability rating of 9 / 10.


What are the PE and PB ratios of MEDPACE HOLDINGS INC (MEDP) stock?

The Price/Earnings (PE) ratio for MEDPACE HOLDINGS INC (MEDP) is 31.22 and the Price/Book (PB) ratio is 29.53.


How financially healthy is MEDPACE HOLDINGS INC?

The financial health rating of MEDPACE HOLDINGS INC (MEDP) is 8 / 10.